Kyverna Therapeutics, Inc.KYTXNASDAQ
Loading
SG&A Expenses Over TimeExpanding
Percentile Rank100
3Y CAGR+62.6%
Studio
Year-over-Year Change

Selling, general, and administrative expenses

3Y CAGR
+62.6%/yr
Annual compound
Percentile
P100
Near historical high
vs 3Y Ago
4.3x
Strong expansion
Streak
4 yr
Consecutive growthExpanding
PeriodValueYoY Change
TTM$34.40M+14.2%
2024$30.13M+141.4%
2023$12.48M+55.9%
2022$8.01M+30.2%
2021$6.15M-